What is INCY's market capitalization?

Incyte has a market capitalization of $19.52B.

Does INCY pay a dividend?

Incyte does not currently pay a dividend, or dividend data is unavailable. Many growth-oriented companies reinvest profits rather than paying dividends.

What is INCY's earnings per share (EPS)?

Incyte's trailing twelve-month earnings per share (EPS) is $2.67. EPS measures the portion of company profit allocated to each outstanding share of stock.

INCY

NASDAQ

Incyte

Price unavailable — configure POLYGON_API_KEY

Overview Earnings Dividends IR

Key Statisticslimited data

Market Cap$19.52B

P/E RatioN/A

Div. Yield—

EPS (TTM)$2.67

52W High—

52W Low—

SectorHealth Care

Industry—

Employees2,844

Price Performance

1 Week+6.23%

3 Month-5.76%

1 Year+53.59%

FinancialsAnnual · QuiverQuant

Revenue$3.70B

Assets$6.78B

Liabilities$1.59B

Net Income$597.60M

About

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

Company Info

WILMINGTON, DE

2,844 employees

Listed 1993-11-03

services-commercial physical & biological research

www.incyte.com

📞(302) 498-6700

WebullFree stocks

Advanced charting, extended hours trading, and free stock for new accounts.

Open Account

Analyze INCY with professional charts— Free to start

Price data sourced from Polygon.io (previous trading day close). Fundamentals from Alpha Vantage. Insider trades from SEC EDGAR. Cached via Cloudflare KV.